Hansoh Pharmaceutical Proposes HKD 0.20 Final Dividend for 2025

The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).

Hansoh Pharmaceutical Group Company Limited has proposed a final ordinary cash dividend of HKD 0.20 per share for the financial year ended 31 December 2025, reflecting the board’s decision to return cash to shareholders following its annual results. Subject to shareholder approval, the stock will trade ex-dividend on 3 July 2026, with the record date set for 9 July 2026 and payment scheduled for 24 July 2026, providing income visibility and a defined timetable for investors tracking the company’s capital return policy.

The dividend will be paid in Hong Kong dollars through the company’s share registrar, Tricor Investor Services Limited, with no withholding tax or adjustments for exchange rate disclosed in the notice. The announcement offers clarity on key dates and amounts for shareholders and signals management’s continued commitment to cash distributions, which may be seen as an indicator of confidence in Hansoh Pharmaceutical’s financial position and future cash generation.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a Hong Kong-listed pharmaceutical company focused on developing, manufacturing and marketing prescription drugs. The group primarily serves the healthcare market with a portfolio of medicines targeting major therapeutic areas in China and potentially other markets, positioning itself as a key player among regional pharma issuers on the Hong Kong Stock Exchange.

Average Trading Volume: 8,419,023

Technical Sentiment Signal: Hold

Current Market Cap: HK$197.2B

Find detailed analytics on 3692 stock on TipRanks’ Stock Analysis page.